1. Home
  2. CLGN vs NXL Comparison

CLGN vs NXL Comparison

Compare CLGN & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

HOLD

Current Price

$0.43

Market Cap

6.0M

Sector

Health Care

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.37

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLGN
NXL
Founded
2004
2010
Country
Israel
United States
Employees
N/A
8
Industry
Industrial Specialties
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0M
7.2M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
CLGN
NXL
Price
$0.43
$0.37
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
40.0K
191.5K
Earning Date
05-27-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$240.45
$15.52
Revenue Next Year
$38.03
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.31
52 Week High
$4.98
$2.00

Technical Indicators

Market Signals
Indicator
CLGN
NXL
Relative Strength Index (RSI) 48.44 51.63
Support Level $0.35 $0.35
Resistance Level $0.45 $0.46
Average True Range (ATR) 0.04 0.03
MACD 0.01 0.01
Stochastic Oscillator 61.46 36.24

Price Performance

Historical Comparison
CLGN
NXL

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: